These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8247317)

  • 21. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA; Borja NL
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
    Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
    Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy.
    Gill JS; Williams G; Ghatei MA; Hetreed AH; Mather HM; Bloom SR
    Diabete Metab; 1990; 16(4):296-302. PubMed ID: 2125013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds.
    Coppini DV; Wellmer A; Weng C; Young PJ; Anand P; Sönksen PH
    J Clin Neurosci; 2001 Nov; 8(6):520-4. PubMed ID: 11683597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus.
    Karsidag S; Morali S; Sargin M; Salman S; Karsidag K; Us O
    Diabetes Res Clin Pract; 2005 Mar; 67(3):211-9. PubMed ID: 15713353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.
    Valensi P; Le Devehat C; Richard JL; Farez C; Khodabandehlou T; Rosenbloom RA; LeFante C
    J Diabetes Complications; 2005; 19(5):247-53. PubMed ID: 16112498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
    Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
    Florkowski CM
    Med J Aust; 1993 Nov; 159(10):711-2. PubMed ID: 8110237
    [No Abstract]   [Full Text] [Related]  

  • 29. Further clinical studies with an aldose reductase inhibitor in diabetic neuropathy.
    van Gerven JM
    Diabet Med; 1993; 10 Suppl 2():35S-38S. PubMed ID: 8334839
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
    Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K; Naruse K; Nakashima E; Sakamoto N
    J Pharmacol Exp Ther; 1996 Jan; 276(1):49-55. PubMed ID: 8558455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.
    Ho EC; Lam KS; Chen YS; Yip JC; Arvindakshan M; Yamagishi S; Yagihashi S; Oates PJ; Ellery CA; Chung SS; Chung SK
    Diabetes; 2006 Jul; 55(7):1946-53. PubMed ID: 16804062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new approach against sugar cataract through aldose reductase inhibitors.
    Banditelli S; Boldrini E; Vilardo PG; Cecconi I; Cappiello M; Dal Monte M; Marini I; Del Corso A; Mura U
    Exp Eye Res; 1999 Nov; 69(5):533-8. PubMed ID: 10548473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 1996 Apr; (1):CD002182. PubMed ID: 17636697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
    Baba M; Kimura K; Suda T; Yagihashi S;
    J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years.
    Didangelos TP; Karamitsos DT; Athyros VG; Kourtoglou GI
    J Diabetes Complications; 1998; 12(4):201-7. PubMed ID: 9647338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
    Ando H; Takamura T; Nagai Y; Kaneko S;
    J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diabetic neuropathy. Current concepts on etiopathogenesis, diagnosis, and treatment].
    Zorrilla Hernández E; Frati Munari A; Lozano Castañeda O; Villalpando Hernández S; Boulton AJ
    Gac Med Mex; 1994; 130(1):18-25. PubMed ID: 7557046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
    Airey M; Bennett C; Nicolucci A; Williams R
    Cochrane Database Syst Rev; 2000; 1996(2):CD002182. PubMed ID: 10796870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
    Florkowski CM; Rowe BR; Nightingale S; Harvey TC; Barnett AH
    Diabetes; 1991 Jan; 40(1):129-33. PubMed ID: 1901808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vibratory perception threshold in diabetic neuropathy.
    Tchen PH; Chiu HC; Fu CC
    J Formos Med Assoc; 1990 Jan; 89(1):23-9. PubMed ID: 1973706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.